According to filings with the U.S. Securities and Exchange Commission, Iliad Biotechnologies is raising up to $115,540,057.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Iliad Biotechnologies
ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate, BPZE1, is the most advanced next generation pertussis vaccine, having completed four Phase 2 clinical trials. ILiAD Biotechnologies, Inc. is a registered Delaware company founded in 2012. Founded in 2020, BioLyo Technologies, BV is a wholly-owned ILiAD subsidiary based in Ghent, Belgium. BioLyo is a Contract Development Manufacturing Organization (CDMO) focused on process and analytical development for Live Bacterial Products.

To learn more about Iliad Biotechnologies, visit https://www.iliadbio.com/
Iliad Biotechnologies Linkedin Page: https://www.linkedin.com/company/iliad-biotechnologies/

Contact:
Keith Rubin, Chief Executive Officer
800-603-3525

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.